Occam Research Ltd is a boutique consultancy specialising in delivering academic quality research to support value demonstration for the pharmaceutical and device industries.
Insights & updates
Sustainability in Health Technology Assessment
In his latest blog, Andrew Briggs, calls for the responsible embedding of sustainability into Health Technology Assessment (HTA), urging critical reflection and warning that serious discussions must first consider global equity - who is at risk of being left behind and who must bear the burden of the environmental cost of technology production?
Greening HTA? Do we need to rethink our approach to value?
At the recent ISPOR meeting in Montreal, Professor Andrew Briggs proposed things that may help or hinder the move to greener HTA methods. The presentation concluded with a warning that attempts to green HTA may in fact “exacerbate the very issues we aim to resolve” and to avoid this we must approach this move with humility and not haste.
Pricing combination products: not how but who?
As combination therapies - especially in oncology - become more commonplace, payers and HTA bodies are struggling to price them fairly. Despite technical progress in methods to attribute value between component treatments, the key question remains: who should implement these solutions?